Questions discussed in this category
(e.g. beta 2 glycoprotein IgM > 20 but <40)
How would the approach differ if the patient had a significant bleeding phenotype vs only minor bruising and mucosal bleeding?
Would the answer differ if the index event was arterial vs venous?
If so, how long after diagnosis do you do so?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
e.g. DITP from eptifibatide after a cardiac intervention
What if the patient is triple-positive or has continued seropositivity on repeat lab testing? What is the appropriate interval of monitoring and does ...
There are multiple difficulties that could be seen: steroids can precipitate a sickle cell crisis, vasculitis and sickle cell can produce similar clin...
What if this was "triple-negative" antiphospholipid syndrome?
1316012914125801244912302123281156710666119758187104509040893788798034
Papers discussed in this category
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04
Blood, 2018 Jul 12
Ann. Intern. Med., 2019 Oct 15
Journal of thrombosis and haemostasis : JTH, 2018-06-07
Rheumatol Int, 2019 Apr 30
Clin Exp Rheumatol, 2012 Sep 25
Wien Klin Wochenschr,
J Rheumatol, 2006 Jul 01
Semin Arthritis Rheum,
Semin Hematol,
Autoimmun Rev, 2017 Sep 09
Lupus, 2021 May 27